Andrea Romero Garces, NP
Adult Health · Paterson, NJNPI 1851918114
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 313 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,198, more than ten times the $125 reported in 2021. Among adult health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 313 payments — averaging $27.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- Amgen$1K
- AbbVie$1K
- AstraZeneca$1K
- Novo Nordisk$728
- Bayer$632
- plus $2K from 14 others
What the payments were for
- Food & beverage$8,737100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 59 | $1,916 |
| Amgen | 41 | $1,290 |
| AbbVie | 50 | $1,084 |
| AstraZeneca | 23 | $1,068 |
| Novo Nordisk | 48 | $728 |
| Bayer | 20 | $632 |
| Ironwood Pharmaceuticals, Inc | 16 | $430 |
| Sumitomo Pharma America, Inc. | 21 | $232 |
| Dexcom, Inc. | 6 | $207 |
| Aimmune Therapeutics, Inc. | 5 | $190 |
| Johnson & Johnson | 5 | $158 |
| Madrigal Pharmaceuticals | 1 | $148 |
| Edwards Lifesciences | 1 | $129 |
| Ardelyx, Inc. | 1 | $126 |
| Lilly USA, LLC | 7 | $114 |
| Pfizer | 1 | $110 |
| Exact Sciences | 3 | $75 |
| Novartis | 2 | $42 |
| Hologic Sales And Service, LLC | 1 | $36 |
| GSK | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$1,191
- Repatha$485
- LINZESS$368
- FARXIGA$344
- EVENITY$275
- Kerendia$271
- BREZTRI$250
- REZDIFFRA$148
- MITRIS RESILIA Mitral Valve$129
- ZENPEP$126
- IBSRELA$126
- VRAYLAR$125
- AIRSUPRA$125
- DEXCOM G6 TRANSMITTER$119
- NURTEC ODT$110
How this compares
$8,746 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 231 | $251,744 |
| KerendiaFinerenone | 142 | $146,924 |
| RybelsusSemaglutide | 84 | $144,794 |
| FarxigaDapagliflozin Propanediol | 119 | $115,695 |
| OzempicSemaglutide | 74 | $84,928 |
| LinzessLinaclotide | 72 | $66,232 |
| VascepaIcosapent Ethyl | 114 | $65,898 |
| Repatha SureclickEvolocumab | 45 | $27,514 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 11 | $26,802 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $24,933 |
| JanuviaSitagliptin Phosphate | 25 | $24,805 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $23,902 |
| GemtesaVibegron | 38 | $22,667 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $20,587 |
| Icosapent Ethyl | 37 | $17,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $1,916 | $259,483242 claims |
| Novo NordiskRybelsus, Ozempic | $728 | $229,721158 claims |
| BayerKerendia | $632 | $146,924142 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,068 | $140,628157 claims |
| AbbVieLinzess | $1,084 | $66,23272 claims |
| AmgenEvenity (2 Syringes) | $1,290 | $26,80211 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $232 | $22,66738 claims |
| GSKTrelegy Ellipta | $31 | $20,58733 claims |
| Lilly USA, LLCTrulicity | $114 | $15,94311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.
Other adult health in Paterson
- Denia PerezPaterson$14K
- Rehana RabPaterson$12K
- June HalperHackensack$358K
- Kara SaggiomoCamden$127K
- Entela AhmetiPomona$75K
- Phyllis McKiernanHackensack$72K
- Denise ForceMiddletown$71K
- Kathleen SenecaHillsborough$64K
- Diane AndresenNorthvale$60K
- Dana BeenstockFreehold$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.